Product Data Sheet

Phenylacetylglycine

Cat. No.: HY-W015061 CAS No.: 500-98-1 Molecular Formula: $C_{10}H_{11}NO_3$

Molecular Weight: 193.2

Endogenous Metabolite; Adrenergic Receptor; Apoptosis Target:

Pathway: Metabolic Enzyme/Protease; GPCR/G Protein; Neuronal Signaling; Apoptosis

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

> -20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (517.60 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	5.1760 mL	25.8799 mL	51.7598 mL
	5 mM	1.0352 mL	5.1760 mL	10.3520 mL
	10 mM	0.5176 mL	2.5880 mL	5.1760 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.83 mg/mL (4.30 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.83 mg/mL (4.30 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.83 mg/mL (4.30 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Phenylacetylglycine is a gut microbial metabolite that can activate β 2AR. Phenylacetylglycine protects against cardiac injury caused by ischemia/reperfusion ^[1] .			
IC ₅₀ & Target	β2 adrenoceptor	Microbial Metabolite	Human Endogenous Metabolite	
In Vitro	Phenylacetylglycine (10-100 μ M; 30 min before H/R injury) reduces disreoxygenation (H/R) injury-induced apoptosis and activates G α i and G α s signaling in neonatal mouse cardiomyocytes (NMCMs) $^{[1]}$.			

MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis Analysis^[1] Cell Line: Neonatal mouse cardiomyocytes (NMCMs) Concentration: 10, 33 and 100 μM Incubation Time: Half an hour before H/R injury Inhibited disreoxygenation injury induced apoptosis. Result: Western Blot Analysis^[1] Cell Line: Neonatal mouse cardiomyocytes (NMCMs) Concentration: 10, 33 and 100 μM **Incubation Time:** Half an hour before H/R injury Result: Significantly decreased the ratio of Bax/Bcl2 and cleaved-caspase 3 expression. Enhanced p-PI3K protein expression. cAMP levels were increased in the early stage and then

CUSTOMER VALIDATION

• Adv Sci (Weinh). 2024 Mar 13:e2306297.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Xu X, et al. The gut microbial metabolite phenylacetylglycine protects against cardiac injury caused by ischemia/reperfusion through activating β2AR. Arch Biochem Biophys. 2021 Jan 15;697:108720.

gradually decreased.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA